CTOs on the Move

Glycomine

www.glycomine.com

 
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Glycomine raised $33M on 08/07/2019

Similar Companies

Banyan Biomarkers Inc

Banyan Biomarkers Inc is a Alachua, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

gloStream

gloStream is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Imago BioSciences

Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.”

Lysogene

Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children. Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen`s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers. Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.